Medpace (NASDAQ:MEDP) Releases FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided EPS guidance of 12.260-13.040 for the period, compared to the consensus EPS estimate of 12.480. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Analysts Set New Price Targets

MEDP has been the subject of several research reports. Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. William Blair reissued a "market perform" rating on shares of Medpace in a research note on Tuesday. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Mizuho dropped their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $349.30.

Medpace Stock Up 3.5 %

Shares of Medpace stock traded up $10.17 on Thursday, hitting $300.71. 254,719 shares of the company traded hands, compared to its average volume of 434,036. Medpace has a 12-month low of $250.05 and a 12-month high of $459.77. The company has a 50-day moving average price of $315.38 and a 200 day moving average price of $332.24. The company has a market cap of $9.09 billion, a PE ratio of 23.85, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period last year, the business earned $3.20 EPS. Equities research analysts anticipate that Medpace will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.